Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Accumulated Expenses: 2019-2024

Historic Other Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $1.1 million.

  • Allogene Therapeutics' Other Accumulated Expenses fell 40.74% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year decrease of 40.74%. This contributed to the annual value of $1.1 million for FY2024, which is 40.74% down from last year.
  • Allogene Therapeutics' Other Accumulated Expenses amounted to $1.1 million in FY2024, which was down 40.74% from $1.8 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Other Accumulated Expenses ranged from a high of $4.8 million in FY2020 and a low of $1.1 million during FY2024.
  • Over the past 3 years, Allogene Therapeutics' median Other Accumulated Expenses value was $1.8 million (recorded in 2023), while the average stood at $1.7 million.
  • In the last 5 years, Allogene Therapeutics' Other Accumulated Expenses spiked by 58.75% in 2020 and then plummeted by 63.58% in 2021.
  • Allogene Therapeutics' Other Accumulated Expenses (Yearly) stood at $4.8 million in 2020, then crashed by 63.58% to $1.7 million in 2021, then grew by 21.38% to $2.1 million in 2022, then decreased by 14.59% to $1.8 million in 2023, then crashed by 40.74% to $1.1 million in 2024.